ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
Open Access
- 14 March 2024
- journal article
- review article
- Published by Springer Nature in npj Precision Oncology
- Vol. 8 (1) , 1-16
Abstract
At least 40% of human cancers are associated with aberrant ERK pathway activity (ERKp). Inhibitors targeting various effectors within the ERKp have been developed and explored for over two decades. Conversely, a substantial body of evidence suggests that both normal human cells and, notably to a greater extent, cancer cells exhibit susceptibility to hyperactivation of ERKp. However, this vulnerability of cancer cells remains relatively unexplored. In this review, we reexamine the evidence on the selective lethality of highly elevated ERKp activity in human cancer cells of varying backgrounds. We synthesize the insights proposed for harnessing this vulnerability of ERK-associated cancers for therapeutical approaches and contextualize these insights within established pharmacological cancer-targeting models. Moreover, we compile the intriguing preclinical findings of ERK pathway agonism in diverse cancer models. Lastly, we present a conceptual framework for target discovery regarding ERKp agonism, emphasizing the utilization of mutual exclusivity among oncogenes to develop novel targeted therapies for precision oncology.Keywords
Funding Information
- Fonds Wetenschappelijk Onderzoek (12Y0120N)
- Deutsche Forschungsgemeinschaft (Ti1028/2-1)
- Bundesministerium für Forschung, Technologie und Raumfahrt (161L0279A)
This publication has 214 references indexed in Scilit:
- Activation of ERK–Drp1 signaling promotes hypoxia‐induced Aβ accumulation by upregulating mitochondrial fission and BACE1 activityFEBS Open Bio, 2021
- Playing cancer at its own game: activating mitogenic signaling as a paradoxical interventionMolecular Oncology, 2021
- Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic DatabasesJAMA Network Open, 2021
- RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progressionJournal of Cellular Physiology, 2019
- A compendium of ERK targetsFEBS Letters, 2017
- Therapeutic targeting of tumor suppressor genesCancer, 2014
- TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next DecadeHuman Mutation, 2014
- MEK1/2 Overactivation Can Promote Growth Arrest by Mediating ERK1/2-Dependent Phosphorylation of p70S6KJournal of Cellular Physiology, 2013
- Involvement of the extracellular signal-regulated protein kinase pathway in phosphorylation of p53 protein and exerting cytotoxicity in human neuroblastoma cells (SH-SY5Y) exposed to acrylamideArchives of Toxicology, 2005
- NITROGEN MUSTARD THERAPYJAMA, 1946